PH12016501026A1 - Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor - Google Patents

Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Info

Publication number
PH12016501026A1
PH12016501026A1 PH12016501026A PH12016501026A PH12016501026A1 PH 12016501026 A1 PH12016501026 A1 PH 12016501026A1 PH 12016501026 A PH12016501026 A PH 12016501026A PH 12016501026 A PH12016501026 A PH 12016501026A PH 12016501026 A1 PH12016501026 A1 PH 12016501026A1
Authority
PH
Philippines
Prior art keywords
alpha
kinase inhibitor
dosage regimen
isoform selective
compound
Prior art date
Application number
PH12016501026A
Other languages
English (en)
Inventor
Di Tomaso Emmanuelle
Germa Marie-Caroline
Massacesi Cristian
Fritsch Christine
Schnell Christian Rene
Tavorath Ranjana
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PH12016501026A1 publication Critical patent/PH12016501026A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12016501026A 2013-12-06 2016-05-31 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor PH12016501026A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306679 2013-12-06
PCT/IB2014/066558 WO2015083101A1 (en) 2013-12-06 2014-12-03 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Publications (1)

Publication Number Publication Date
PH12016501026A1 true PH12016501026A1 (en) 2016-07-04

Family

ID=49876516

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501026A PH12016501026A1 (en) 2013-12-06 2016-05-31 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Country Status (22)

Country Link
US (4) US20170000778A1 (cg-RX-API-DMAC7.html)
EP (2) EP3076969B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016539149A (cg-RX-API-DMAC7.html)
KR (1) KR20160095035A (cg-RX-API-DMAC7.html)
CN (1) CN105979947A (cg-RX-API-DMAC7.html)
AU (2) AU2014358773A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016011811A2 (cg-RX-API-DMAC7.html)
CA (1) CA2930359C (cg-RX-API-DMAC7.html)
CL (1) CL2016001361A1 (cg-RX-API-DMAC7.html)
DK (1) DK3076969T3 (cg-RX-API-DMAC7.html)
ES (1) ES2899167T3 (cg-RX-API-DMAC7.html)
HU (1) HUE057092T2 (cg-RX-API-DMAC7.html)
IL (1) IL245709B (cg-RX-API-DMAC7.html)
MX (1) MX378409B (cg-RX-API-DMAC7.html)
PH (1) PH12016501026A1 (cg-RX-API-DMAC7.html)
PL (1) PL3076969T3 (cg-RX-API-DMAC7.html)
PT (1) PT3076969T (cg-RX-API-DMAC7.html)
RU (1) RU2680246C1 (cg-RX-API-DMAC7.html)
SI (1) SI3076969T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000179A1 (cg-RX-API-DMAC7.html)
TW (1) TWI666019B (cg-RX-API-DMAC7.html)
WO (1) WO2015083101A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077445A1 (en) * 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
GB202010627D0 (en) * 2020-07-10 2020-08-26 Qbd (Qs-Ip) Ltd Blocking method

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
EP0383919A4 (en) 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
EP0610433A1 (en) 1991-11-08 1994-08-17 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
ATE378406T1 (de) 1992-08-31 2007-11-15 Ludwig Inst Cancer Res Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
DE69331228D1 (en) 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
JP3398382B2 (ja) 1992-10-28 2003-04-21 ジェネンテク，インコーポレイテッド 血管内皮細胞増殖因子アンタゴニスト
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO1995002597A1 (en) 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
WO1995017182A1 (en) 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
BR9610745A (pt) 1995-12-08 1999-07-13 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il) metil-2-quinolinona inibindo a transferase da proteina farnesil
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
WO1998005769A2 (en) 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
ATE311884T1 (de) 1997-07-12 2005-12-15 Cancer Rec Tech Ltd Cyclin-abhängige-kinase inhibierende purinderivate
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
WO2001000245A2 (en) 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
AU6014900A (en) 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
DE60029007T2 (de) 1999-11-05 2007-01-11 Astrazeneca Ab Quinazolin-derivate als vegf-hemmer
ES2438535T3 (es) 1999-12-06 2014-01-17 Geistlich Pharma Ag Taurolidina o taurultamo para uso en el tratamiento de tumores de próstata, de colon, de pulmón y para el tratamiento del glioblastoma multiforme recurrente
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
DK1274718T3 (da) 2000-04-12 2007-02-12 Genaera Corp En fremgangsmåde til forberedelse af 7.alpha.-hydroxy 3-aminosubstituerede steroler vee en ubeskyttet 7.alpha.-hydroxy gruppe
US7157466B2 (en) 2000-06-30 2007-01-02 Smithkline Beecham (Cork) Limited Quinazoline ditosylate salt compounds
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
CA2434802C (en) 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1404689A1 (en) 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
NZ535985A (en) 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2013542228A (ja) * 2010-11-08 2013-11-21 ノバルティス アーゲー Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
US9006270B2 (en) * 2011-06-21 2015-04-14 Novartis Ag Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
EP2601965A1 (en) * 2011-12-06 2013-06-12 Apeiron Biologics AG Compositions for preventing or treating adverse reactions of EGFR inhibition
RU2630975C2 (ru) 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы

Also Published As

Publication number Publication date
CN105979947A (zh) 2016-09-28
US20180078540A1 (en) 2018-03-22
KR20160095035A (ko) 2016-08-10
US10434092B2 (en) 2019-10-08
ES2899167T3 (es) 2022-03-10
AU2014358773A1 (en) 2016-06-02
TWI666019B (zh) 2019-07-21
SI3076969T1 (sl) 2021-12-31
US20200069670A1 (en) 2020-03-05
IL245709B (en) 2021-03-25
BR112016011811A2 (pt) 2017-08-08
MX2016007376A (es) 2017-05-11
PL3076969T3 (pl) 2022-01-17
EP4000619A1 (en) 2022-05-25
TW201609096A (zh) 2016-03-16
IL245709A0 (en) 2016-07-31
CL2016001361A1 (es) 2017-02-10
US20170000778A1 (en) 2017-01-05
EP3076969B1 (en) 2021-09-01
AU2017245292A1 (en) 2017-11-02
US20210196696A1 (en) 2021-07-01
JP2016539149A (ja) 2016-12-15
MX378409B (es) 2025-03-10
HUE057092T2 (hu) 2022-04-28
RU2680246C1 (ru) 2019-02-19
DK3076969T3 (da) 2021-11-22
EP3076969A1 (en) 2016-10-12
TN2016000179A1 (en) 2017-10-06
AU2017245292B2 (en) 2018-09-27
CA2930359C (en) 2022-03-01
CA2930359A1 (en) 2015-06-11
PT3076969T (pt) 2021-11-23
HK1223549A1 (zh) 2017-08-04
WO2015083101A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX2013012588A (es) Inhibidores de cinasa.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12016502355A1 (en) Pharmaceutical composition
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
NZ714963A (en) Compositions and methods for treating anemia
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
PH12016502353A1 (en) Pharmaceutical composition
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12016502352A1 (en) Pharmaceutical composition
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
ME02405B (me) Spojevi pirazola као inhibitori sglt1
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX358470B (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом